ECSP077222A - Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4) - Google Patents

Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4)

Info

Publication number
ECSP077222A
ECSP077222A EC2007007222A ECSP077222A ECSP077222A EC SP077222 A ECSP077222 A EC SP077222A EC 2007007222 A EC2007007222 A EC 2007007222A EC SP077222 A ECSP077222 A EC SP077222A EC SP077222 A ECSP077222 A EC SP077222A
Authority
EC
Ecuador
Prior art keywords
human
interleucine
monoclonal antibodies
antibodies against
human monoclonal
Prior art date
Application number
EC2007007222A
Other languages
English (en)
Inventor
Herrera Jose M Carballido
Vries Jan E De
Christoph Schwaerzler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077222(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0417306A external-priority patent/GB0417306D0/en
Priority claimed from GB0417301A external-priority patent/GB0417301D0/en
Priority claimed from GB0417302A external-priority patent/GB0417302D0/en
Priority claimed from GB0417305A external-priority patent/GB0417305D0/en
Priority claimed from GB0417303A external-priority patent/GB0417303D0/en
Priority claimed from GB0417304A external-priority patent/GB0417304D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP077222A publication Critical patent/ECSP077222A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos que son específicos para la interleucina-4 humana, y su uso en el tratamiento de enfermedades mediadas por IL-4 y/o IgE.
EC2007007222A 2004-08-03 2007-02-02 Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4) ECSP077222A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0417306A GB0417306D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417301A GB0417301D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417302A GB0417302D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417305A GB0417305D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417303A GB0417303D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417304A GB0417304D0 (en) 2004-08-03 2004-08-03 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP077222A true ECSP077222A (es) 2007-03-29

Family

ID=35457817

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007222A ECSP077222A (es) 2004-08-03 2007-02-02 Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4)

Country Status (28)

Country Link
US (2) US7740843B2 (es)
EP (2) EP2327726A3 (es)
JP (1) JP4808712B2 (es)
KR (1) KR101245996B1 (es)
CN (1) CN101001877B (es)
AR (1) AR050044A1 (es)
AU (1) AU2005268932B2 (es)
BR (1) BRPI0514124B8 (es)
CA (1) CA2574289C (es)
CY (1) CY1115524T1 (es)
DK (1) DK1817343T3 (es)
EC (1) ECSP077222A (es)
ES (1) ES2504415T3 (es)
HR (1) HRP20140888T1 (es)
IL (1) IL180789A (es)
MA (1) MA28981B1 (es)
MX (1) MX2007001342A (es)
MY (1) MY141851A (es)
NO (1) NO20070854L (es)
NZ (1) NZ552637A (es)
PE (1) PE20060560A1 (es)
PL (1) PL1817343T3 (es)
PT (1) PT1817343E (es)
SG (1) SG155177A1 (es)
SI (1) SI1817343T1 (es)
TN (1) TNSN07036A1 (es)
TW (1) TWI356828B (es)
WO (1) WO2006013087A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323645B2 (en) * 2005-03-24 2012-12-04 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2009005673A1 (en) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
CA2796633C (en) 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
WO2012106587A1 (en) 2011-02-04 2012-08-09 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
HRP20231139T1 (hr) 2014-05-06 2024-01-05 F. Hoffmann - La Roche Ag Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
CA3023446A1 (en) 2016-05-10 2017-11-16 Hennepin Healthcare Research Institute Cytokine signaling immunomodulators and methods
CN108409860B (zh) * 2017-02-10 2021-10-15 三生国健药业（上海）股份有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
EP3655961A4 (en) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology HEALTHY AND SICK BARRIER TISSUE CELL ATLAS
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
AU2020231343B2 (en) 2019-03-06 2026-03-26 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CN114957472B (zh) * 2020-06-22 2023-10-31 南京融捷康生物科技有限公司 抗IL-4Rα的单域抗体以及应用和药物
CN118355034A (zh) 2021-12-30 2024-07-16 瑞泽恩制药公司 施用il-4/il-13拮抗剂以减弱特应性进程的方法
CN118388645B (zh) * 2024-05-17 2024-11-22 康立泰生物医药(青岛)有限公司 一种抗人白介素4抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU629536B2 (en) 1988-02-02 1992-10-08 Schering Biotech Corporation Method of reducing immunoglobulin e responses
CA2071908C (en) * 1989-12-20 2002-04-30 Lata Ramanathan Antibody antagonists of human interleukin-4
DE69321218T2 (de) 1992-02-19 1999-02-18 Schering Corp., Kenilworth, N.J. Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
WO1994004180A2 (en) 1992-08-20 1994-03-03 Schering Corporation Novel uses of il-4 and/or il-10, and antibodies against the same
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
WO1995007301A1 (en) * 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US20020002132A1 (en) * 2000-05-26 2002-01-03 Pluenneke John D. Use of interleukin-4 antagonists and compositions thereof
AU2003299641C1 (en) 2002-12-16 2016-06-02 Cormorant Pharmaceuticals Ab Human monoclonal antibodies against interleukin 8 (IL-8)
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine

Also Published As

Publication number Publication date
IL180789A (en) 2017-01-31
CA2574289C (en) 2014-09-16
SG155177A1 (en) 2009-09-30
PE20060560A1 (es) 2006-06-27
TW200617024A (en) 2006-06-01
CN101001877A (zh) 2007-07-18
EP1817343A1 (en) 2007-08-15
US7740843B2 (en) 2010-06-22
DK1817343T3 (da) 2014-09-15
TWI356828B (en) 2012-01-21
ES2504415T3 (es) 2014-10-08
BRPI0514124B1 (pt) 2017-01-31
HRP20140888T1 (hr) 2014-10-24
BRPI0514124B8 (pt) 2021-05-25
TNSN07036A1 (en) 2008-06-02
EP2327726A3 (en) 2012-07-11
HK1109158A1 (en) 2008-05-30
MY141851A (en) 2010-07-16
KR20070047299A (ko) 2007-05-04
PL1817343T3 (pl) 2014-11-28
CA2574289A1 (en) 2006-02-09
WO2006013087A1 (en) 2006-02-09
IL180789A0 (en) 2007-06-03
BRPI0514124A (pt) 2008-05-27
JP4808712B2 (ja) 2011-11-02
CY1115524T1 (el) 2017-01-04
EP1817343B1 (en) 2014-06-25
WO2006013087A8 (en) 2007-03-01
MX2007001342A (es) 2007-04-02
AR050044A1 (es) 2006-09-20
US20100254993A1 (en) 2010-10-07
AU2005268932B2 (en) 2009-06-25
NO20070854L (no) 2007-04-24
SI1817343T1 (sl) 2014-09-30
KR101245996B1 (ko) 2013-03-20
EP2327726A2 (en) 2011-06-01
JP2008507985A (ja) 2008-03-21
NZ552637A (en) 2010-02-26
US20080241160A1 (en) 2008-10-02
MA28981B1 (fr) 2007-11-01
PT1817343E (pt) 2014-09-09
CN101001877B (zh) 2012-09-26
AU2005268932A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
CY1115524T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εναντι της ανθρωπινης il-4
CR7875A (es) Variantes de inmunoglobina y usos de esto
BRPI0507118A (pt) polipeptìdeos de interferon humano modificado e seus usos
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
TR201821029T4 (tr) Geliştirilmiş antı-IL-23p19 antikorları.
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
HN2005029978A (es) Formulaciones
CL2007001665A1 (es) Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
CY1120904T1 (el) Βελτιωμενη γελη τεστοστερονης και μεθοδος χρησεως στην αγωγη του υπογοναδισμου
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DK1844074T3 (da) Humane antistoffer og proteiner
PA8600601A1 (es) Ligandos de receptores de cannabinoides y sus usos
NO20091064L (no) Antistoffer mot IL-17A
AR061171A1 (es) Proteinas de union al factor de crecimiento de hepatocitos (fch)
ATE461217T1 (de) Glp-1-verbindungen
UA94221C2 (en) Lipocalin protein
CR9763A (es) Uso de una sola dosis de moleculas de union especificas cd20
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
CR10237A (es) Anticuerpos contra la il-22 humana y usos para los mismos
CY2022028I1 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina